Quick Summary:
Gain a competitive edge in the growing global market for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics with this exhaustive market research report. Estimated at US$28.7 Billion in 2022 and projected to reach a revised size of US$51.9 Billion by 2030, the ADHD Therapeutic sector is witnessing profound growth. This report grants you a comprehensive understanding of the competitive landscape, promising segments, and geographies to help strategize and make informed decisions.
From entrenched markets like the U.S. and Germany to rapidly growing ones like China, your intervention points will be rivetted. Your decision-making process will also benefit from a thorough dissection of segments such as Stimulant and Non-Stimulant. The report's analysis showcases a list of 27 key players like Eli Lilly and Shire plc, giving you an insight into their market shares. What's more, as an added bonus, the report includes complimentary updates for one year, ensuring you stay abreast of the latest trends and shifts.
Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market to Reach $51.9 Billion by 2030
The global market for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics estimated at US$28.7 Billion in the year 2022, is projected to reach a revised size of US$51.9 Billion by 2030, growing at a CAGR of 7.7% over the analysis period 2022-2030. Stimulant, one of the segments analyzed in the report, is projected to record 7.2% CAGR and reach US$43 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Non-Stimulant segment is readjusted to a revised 10.2% CAGR for the next 8-year period.
The U.S. Market is Estimated at $8.4 Billion, While China is Forecast to Grow at 7.2% CAGR
The Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics market in the U.S. is estimated at US$8.4 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$9 Billion by the year 2030 trailing a CAGR of 7.2% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.9% and 6.4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 5.9% CAGR.Select Competitors (Total 27 Featured) -
- Alcobra Ltd.
- Amarantus Bioscience Holdings, Inc.
- Curemark, LLC
- Eli Lilly and Company
- Intellipharmaceutics International, Inc.
- Janssen Global Services, LLC
- Mallinckrodt PLC
- Mylan NV
- Neos Therapeutics, Inc.
- Neurovance, Inc.
- Noven Pharmaceuticals, Inc.
- Pfizer Inc.
- Shire plc
- Supernus Pharmaceuticals, Inc.
- Tris Pharma, Inc.
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
What is the estimated value of the Global Market for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics?
What is the growth rate of the Global Market for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics?
What is the forecasted size of the Global Market for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics?
Who are the key companies in the Global Market for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics?
| Report Attribute | Details |
|---|---|
| No. of Pages | 186 |
| Published | December 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 28.7 Billion |
| Forecasted Market Value ( USD | $ 51.9 Billion |
| Compound Annual Growth Rate | 7.7% |
| Regions Covered | Global |
Table of Contents
Companies Mentioned
A selection of companies mentioned in this report includes:
- Alcobra Ltd.
- Amarantus Bioscience Holdings, Inc.
- Curemark, LLC
- Eli Lilly and Company
- Intellipharmaceutics International, Inc.
- Janssen Global Services, LLC
- Mallinckrodt PLC
- Mylan NV
- Neos Therapeutics, Inc.
- Neurovance, Inc.
- Noven Pharmaceuticals, Inc.
- Pfizer Inc.
- Shire plc
- Supernus Pharmaceuticals, Inc.
- Tris Pharma, Inc.
